An interventional study of High-frequency percutaneous femoral nerve stimulation and Low-frequency percutaneous femoral nerve stimulation in Patellar Tendinopathy, sponsored by Hospital Clinic of Barcelona. Completed at 1 site in Spain. Open to male participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Musculoskeletal Pain with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Musculoskeletal Pain · Spain.
Among the 45 studies in Musculoskeletal Pain with a site in Spain, this one is the 29th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2025, is one of 27 with no phase, and was the 37th registered.
518 studies on the registry are indexed under Musculoskeletal Pain; 127 are open to participants now.
Browse Musculoskeletal Pain studies →11 of the 45 studies in Musculoskeletal Pain with a site in Spain are open now. Recruiting first, the newest first:
Universidad San Jorge · Sites in Spain
Ages 18–65 · Healthy volunteers
University of Alcala · Sites in Spain
Ages 18–80
Ander Cervantes Benítez · Sites in Spain
Ages 18+ · Healthy volunteers
Universidad Autonoma de Madrid · Sites in Spain
Ages 18–65
Universidad Autonoma de Madrid · Sites in Spain
Ages 18–65
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 66 Musculoskeletal Pain studies recruiting now, 30 (45%) set no upper age limit and 30 (45%) stop at 75 or younger; 8 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 40 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 69 across 373 interventional studies indexed under Musculoskeletal Pain.
Median enrollment 66 across the 30 interventional studies, 200 across the 15 observational. Of the 25 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 45 have an industry lead sponsor. The 10 most frequent:
Hospital Clinic of Barcelona is the lead sponsor of 327 studies on the registry; 54 are open to participants now.
Hospital Clinic of Barcelona has 1 study filed under Musculoskeletal Pain — fewer than ten, so there is no comparison to draw.
3 of the studies in Musculoskeletal Pain with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06900231Universitat de LleidaKnowledge, Attitudes, and Beliefs About Musculoskeletal Pain Among Primary Care Health Professionals in Spain. | 2026-11 |
| NCT07844707Universidad San JorgeExercise and Health Education for Musculoskeletal Health in Industrial Workers | 2027-03 |
| NCT07756229Ander Cervantes BenítezClinical and Brain Activity Assessment Before and After Physiotherapy in People With Chronic Non-specific Neck Pain | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 45 studies in Musculoskeletal Pain with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Peripheral nerve stimulation (PNS) is used to manage musculoskeletal pain and may also influence the neural mechanisms involved in voluntary muscle activation. However, whether different stimulation protocols produce distinct effects on muscle strength in individuals with persistent musculoskeletal pain remains unclear.
This randomized, blinded, crossover clinical trial investigates the acute effects of three femoral nerve stimulation protocols on quadriceps muscle function in individuals with persistent patellar tendinopathy. Each participant receives three interventions in a randomized sequence, separated by washout periods of at least 7 days: (1) high-frequency percutaneous peripheral nerve stimulation (HF-pPNS; 100 Hz), (2) low-frequency percutaneous peripheral nerve stimulation (LF-pPNS; 2 Hz), and (3) sensory-level transcutaneous electrical nerve stimulation (s-TENS; 100 Hz). Percutaneous interventions are administered under ultrasound guidance, whereas s-TENS is delivered using surface electrodes.
Quadriceps maximal voluntary contraction (MVC) and rate of force development (RFD) are assessed before stimulation and at 2, 10, 15, and 30 minutes after each intervention. Pain experienced during muscle strength testing, intervention tolerability, and adverse events are also evaluated.
The primary objective is to determine whether these stimulation protocols produce different acute changes in voluntary quadriceps force production. The study also examines interindividual variability in motor responses and explores their associations with pain during voluntary contraction and baseline clinical status.
The criteria were revised on the registry on Nov 16, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive HF-pPNS as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.
Device: High-frequency percutaneous femoral nerve stimulation
Participants receive LF-pPNS as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.
Device: Low-frequency percutaneous femoral nerve stimulation
Participants receive s-TENS targeting the femoral nerve as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.
Device: Transcutaneous electrical nerve stimulation
High-frequency percutaneous peripheral nerve stimulation (HF-pPNS) is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Valencia, Spain), which generates symmetrical biphasic pulses. The femoral nerve is identified at the inguinal level using a SonoScape E1 Exp ultrasound system (SonoScape Medical Corp., Shenzhen, China). Under real-time ultrasound guidance, a sterile acupuncture needle (0.30 × 50 mm) is inserted in-plane and positioned lateral to the femoral nerve, avoiding adjacent vessels. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Stimulation is administered at 100 Hz in five 5-second trains separated by 55-second rest intervals. Intensity is adjusted to the highest pain-free current eliciting visible quadriceps contraction. Participants receive one session, with at least 7 days between crossover conditions.
Also known as: HF-pPNS
Low-frequency percutaneous peripheral nerve stimulation (LF-pPNS) is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Valencia, Spain), which generates symmetrical biphasic pulses. The femoral nerve is identified at the inguinal level using a SonoScape E1 Exp ultrasound system (SonoScape Medical Corp., Shenzhen, China). Under real-time ultrasound guidance, a sterile acupuncture needle (0.30 × 50 mm) is inserted in-plane and positioned lateral to the femoral nerve, avoiding adjacent vessels. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Stimulation is administered continuously at 2 Hz for 16 minutes. Intensity is adjusted to the highest pain-free current eliciting visible quadriceps contraction. Participants receive one session, with at least 7 days between crossover conditions.
Also known as: LF-pPNS
Sensory-level transcutaneous electrical nerve stimulation (s-TENS) is administered targeting the femoral nerve at the inguinal level. The femoral nerve is identified under ultrasound guidance (SonoScape E1 Exp, SonoScape Medical Corp., China), and a self-adhesive surface electrode (5 × 5 cm) is positioned over the nerve. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Electrical stimulation is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Spain), generating symmetrical biphasic pulses continuously at 100 Hz for 16 minutes. Intensity is individually adjusted to elicit a clear paresthetic sensation without visible quadriceps contraction. Each participant receives one s-TENS session, with a minimum 7-day washout between crossover conditions.
Also known as: s-TENS
Change in Quadriceps Maximal Isometric Voluntary Contraction
Quadriceps maximal voluntary isometric contraction (MVC) is measured on the symptomatic limb using a Chronojump Force Sensor Kit (Chronojump, Barcelona, Spain). Participants are seated with the hip flexed at 90° and the knee positioned at 60°. Following a standardized warm-up and familiarization procedure, participants perform three 4-second maximal voluntary isometric knee-extension contractions, separated by 10-second rest intervals. Real-time visual force feedback is provided, and participants are instructed to contract as fast and as hard as possible from a relaxed state. MVC is defined as the highest peak force recorded across the three trials, expressed in Newtons (N). Absolute and relative changes from baseline are assessed following each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS).
Time frame: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.
Change in Quadriceps Rate of Force Development
Quadriceps rate of force development (RFD) is assessed on the symptomatic limb using a Chronojump Force Sensor Kit (Chronojump, Barcelona, Spain). Participants perform three 4-second maximal voluntary isometric knee-extension contractions, separated by 10-second rest intervals, while instructed to contract as fast and as hard as possible. RFD is calculated from the force-time curve as the slope of force increase during the first 250 milliseconds following contraction onset, expressed in Newtons per second (N/s). Absolute and relative changes from baseline are assessed following each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS).
Time frame: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.
Incidence of Adverse Events Assessed Through Post-Intervention Questionnaires
Adverse events potentially associated with peripheral nerve stimulation are assessed using a structured questionnaire completed at the end of each experimental session. Participants report the presence and intensity of sensory symptoms (pain, burning, itching), local skin reactions (erythema, swelling, bruising), and systemic symptoms (fatigue, headache, nausea). Additional unexpected symptoms can also be reported. Symptom intensity is assessed using a numerical rating scale (NRS; 0-10). Adverse events are recorded by type and severity, and their incidence is expressed as the number and percentage of participants reporting each event under each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS). Differences in adverse event frequency and intensity are evaluated across stimulation conditions.
Time frame: Immediately after each intervention session.
Pain Intensity Evoked by Quadriceps Contraction
Pain intensity experienced during quadriceps maximal voluntary isometric contraction (MVC) is assessed using a 10-cm visual analog scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Participants report the intensity of pain experienced during the strength-testing procedure immediately after its completion. Pain scores are recorded for each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS) to characterize pain experienced during voluntary force production and explore its association with changes in quadriceps strength.
Time frame: Immediately after post-intervention quadriceps strength testing during each experimental session.
Plan to share: Yes — De-identified individual participant data underlying the results reported in the published article will be available from the corresponding author upon reasonable request. These data may include maximal voluntary contraction (MVC), rate of force development (RFD), pain ratings, baseline clinical characteristics, stimulation conditions, and adverse events. Data sharing will be subject to applicable ethical approvals, institutional policies, and data protection requirements. Requests will be evaluated based on their scientific rationale and methodological soundness.
Time frame: De-identified individual participant data will be available upon reasonable request beginning at the time of publication of the study results and for a period of five years thereafter.
Access criteria: De-identified individual participant data underlying the published results will be available to qualified researchers upon reasonable request to the corresponding author. Requests must include a scientifically sound research proposal describing the intended use of the data. Access will be subject to approval by the research team and compliance with applicable ethical, institutional, and data protection requirements. A data-sharing agreement may be required before data transfer.
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Jan 2026, 3 months.
Of 226 non-industry interventional studies with no phase under Musculoskeletal Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's 3 months is below that.
Counting every sponsor, half of 239 studies reached it within 12 months; a quarter within 5 and three quarters within 32.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Nov 2025 → Jan 2026 and completion Dec 2025 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Clinic of Barcelona →